Front Row Advisors’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Front Row Advisors’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14	Closed	-$1K	–	1062
2019 Q4	$1K	Hold	14	–	–	﹤0.01%	884
2019 Q3	$1K	Buy	14 +5	+56%	+$406	﹤0.01%	893
2019 Q2	$1K	Buy	+9	New	+$890	﹤0.01%	992

Other funds holding TARO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Front Row Advisors's TARO Position: Q1 2020 in Review

Front Row Advisors sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2020, closing a stake of 14 shares — an estimated $1K sold.

Front Row Advisors first reported a position in TARO in Q2 2019 and held it in 3 quarters. The position peaked at $1K in Q4 2019. 90 funds tracked by Wall St. Rank hold TARO as of Q1 2020.

Front Row Advisors reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2020 after selling out during the quarter.
Front Row Advisors sold 14 Taro Pharmaceutical Industries Ltd. shares in Q1 2020, an estimated $1K.
Front Row Advisors first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2019 and held it in 3 quarters.
Front Row Advisors's Taro Pharmaceutical Industries Ltd. position peaked at $1K in Q4 2019.
90 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2020.

Based on Front Row Advisors's 13F filing for Q1 2020, filed 8 May 2020.